NFKB1 and colon carcinoma: Therefore, it is likely that administration of anti‐CD47 and/or anti‐SIRPα mAb interferes Akt and NF‐κB activation in macrophages, influencing macrophages migration, survival, cytokines production, and/or angiogenesis in tumor sites.44 We have demonstrated that anti‐SIRPα mAb promotes phagocytic activity of macrophages not only against hepatoma but also against colon carcinoma cells, but anti‐CD47 mAb does not.